CME/SAM. Software-Automated Counting of Ki-67 Proliferation Index Correlates With Pathologic Grade and Disease Progression of Follicular Lymphomas
|
|
- Isabel Byrd
- 5 years ago
- Views:
Transcription
1 AJCP / Original Article Software-Automated Counting of Ki-67 Proliferation Index Correlates With Pathologic Grade and Disease Progression of Follicular Lymphomas Mark A. Samols, MD, PhD, 1 Nathan E. Smith, MD, 1 Jonathan M. Gerber, MD, 2 Milena Vuica- Ross, MD, PhD, 1 Christopher D. Gocke, MD, 1 Kathleen H. Burns, MD, PhD, 1 Michael J. Borowitz, MD, PhD, 1 Toby C. Cornish, MD, PhD, 1 and Amy S. Duffield, MD, PhD 1 From the 1 Department of Pathology and 2 Division of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD. Key Words: Follicular lymphoma; Ki-67; Automated counting; Histologic grade; Proliferation index; Quantitation DOI: 1.139/AJCPTMA1F6LWYTQV ABSTRACT Objectives: To examine the accuracy of software-assisted measurement of the Ki-67 proliferation index (PI) and its correlation with the grade and clinical progression of follicular lymphoma (FL). Methods: High-power field equivalents were extracted from H&E- and Ki-67 immunostained slides of FL, and a nuclear quantitation algorithm was used to calculate a PI. Representative fields were manually counted for validation with close agreement. Results: The PI was significantly higher in World Health Organization grade 3 FL than grade 1 to 2 FL. Disease progression, as defined by subsequent treatment with radiation or cytotoxic chemotherapy, was also significantly associated with elevated PI but not pathologic grade. Conclusions: These data show that software-automated quantitation of Ki-67 can provide both a useful adjunct to pathologic grade in FL and improved prognostic information for patients. Upon completion of this activity you will be able to: describe the criteria used to grade follicular lymphoma. discuss the significance of the Ki-67 proliferation index in follicular lymphoma. explain strategies for software-assisted quantification of immunostains. The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module. The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. Questions appear on p 596. Exam is located at Follicular lymphoma (FL) is the most common lowgrade B-cell lymphoma and is characterized by neoplastic expansion of follicle center cells. Disease progression in FL is often relatively slow, although more rapid progression is associated with a high score on the FL International Prognostic Index, the presence of associated diffuse large B-cell lymphoma (DLBCL), and high histologic grade. 1 Pathologic examination of the tissue is required to determine the histologic grade; currently, this is determined by calculating the mean number of centroblasts per 4 high-power field (hpf) in 1 neoplastic follicles. 2,3 In the 21 World Health Organization (WHO) classification, 4 FL was subdivided into 3 grades: grade 1 was defined as having to 5 centroblasts/hpf, grade 2 with 6 to 15 centroblasts/hpf, and grade 3 with greater than 15 centroblasts/hpf. Grade 3 was further subdivided into 3A, in which CME/SAM Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV 579 Samols_ indd 579
2 Samols et al / Ki-67 in Follicular Lymphoma the neoplastic follicles contain a mixture of centroblasts and centrocytes, and grade 3B, in which the neoplastic follicles only contain centroblasts. The 3 grades were shown to correlate roughly with disease prognosis, with grades 1 and 2 having a more indolent course and prolonged survival as compared with grade 3 tumors. 5,6 In the 28 WHO classification, grades 1 and 2 were combined into grade 1 to 2 (low-grade) FL due to poor interobserver reproducibility and lack of significant survival differences between grades 1 and 2. 2,7,8 The correlation between the Ki-67 proliferation index (PI), histologic grade, and prognosis has been studied in several lymphomas, including FL. These studies relied on various methods for determining Ki-67 PI, including estimating positive cells as well as the more precise but laborious manual counting of cells. In general, these studies demonstrate that high proliferative activity is associated with more aggressive lymphomas, although there was not a clear consensus regarding a cutoff Ki-67 PI at which a lymphoma can be designated high or low grade Because it is impractical to count positive cells manually for routine diagnostic purposes and visual estimates are subjective and dependent on observer experience, image analysis is becoming increasingly commonplace for the quantitation of biomarkers in formalin-fixed, paraffin-embedded tissue. Several manufacturers have received Food and Drug Administration clearance to market image analysis software for the measurement of estrogen receptor, progesterone receptor, and HER2 expression in breast cancer, and these methods are well established in current clinical practice Studies have shown these methods to be accurate and comparable to carefully performed manual quantitation Thus, the use of image analysis methods can provide consistent and objective measurements of labeling indices. Several studies have examined the use of image analysis software to measure the nuclear staining index of Ki-67 in lymphomas. A few studies have focused on the measurement of PI in FL and found that automated Ki-67 counts were similar to manual counts; however, these studies were either performed before modern image analysis techniques were developed or lacked associated clinical information. 2,21 Interestingly, a recent study that used automated methods to quantify the PI concluded that software-assisted counting provided no significant association with either pathologist estimate or survival in DLBCL. 22 In this study, we used current technology for slide scanning and quantitation of immunohistochemical (IHC) labeling to determine the Ki-67 PI and investigated its relationship to histologic grade and disease progression in FL. We found that image analysis provides a relatively rapid and reproducible method for objective quantitation of Ki-67 PI in FL and that PI correlates with both histologic grade and clinical progression of disease. Materials and Methods The pathology database at The Johns Hopkins Hospital was searched using the keywords follicular and lymphoma. All cases of FL from January 21 to December 21 were identified. Of note, rituximab was in use at our institution by 21, and core biopsy specimens were excluded from the study. Only cases that had at least 1 H&E slide as well as selected corresponding IHC stains (CD2, CD3, Bcl-2, and Ki-67) available for review were included. The H&E and IHC stains were reviewed in all cases. Since the WHO classification for FL changed with the 28 edition, the collected cases follow either the old 3-tiered or newer 2-tiered grading system, depending on when the original diagnosis was made. H&E and Ki-67 (Ventana Medical Systems, Tucson, AZ) slides were scanned using the 2 objective (.498 mm/pixel) on a ScanScope CS slide scanner (Aperio, San Diego, CA). Ten hpf-equivalent fields (55 55 mm) of representative neoplastic follicles were selected using the H&E slides, and the corresponding fields were extracted from the Ki-67 whole slide image. Only intact fields without crush or other artifact were selected. The extracted fields were uploaded to a Spectrum digital slide repository (Aperio). An analysis macro based on the Nuclear Quantitation algorithm from Aperio s image analysis tool box was then tuned using a subset of images representing low, medium, and high Ki-67 indices. The algorithm parameters used in this study are provided in Table 1. After tuning, the analysis macro was applied to the entire image set, identifying nuclei and classifying them as positive or negative for Ki-67. Briefly, the Aperio Nuclear Quantitation algorithm first separates 3,3 -diaminobenzidine (DAB) and hematoxylin stains by applying color deconvolution using the nuclear (hematoxylin) and positive (DAB) optical density vectors given in Table The hematoxylin image is smoothed by applying an averaging filter with a radius of 3 pixels. The nuclei are segmented from background using intensity-based segmentation with an intensity range of to 2. A curvaturebased watershed algorithm separates overlapping nuclei, and the resulting nuclei are filtered using shape descriptors, including size, roundness, compactness, and elongation. 24 Nuclei with a mean DAB value of less than 19 are classified as positive. For validation of automated counts, 1 fields from 3 cases representing low, medium, and high Ki-67 indices were manually counted using a custom ImageJ-based macro (National Institutes of Health, Bethesda, MD). Using this macro, human observers (M.A.S. and N.E.S.) annotated each nucleus as positive or negative for Ki-67 using differentcolored markers. The annotated images were saved, and the nuclear markers were counted by the software. Correlation between the automated and manual counts was calculated using a Pearson correlation coefficient. 58 Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV Samols_ indd 58
3 AJCP / Original Article Table 1 Parameters for Nuclear Quantitation From Aperio s Image Analysis Tool Box Parameter Clinical data were collected from The Johns Hopkins electronic patient records in accordance with institutional review board approved protocol NA_ Treatment was classified as radiation therapy and/or cytotoxic chemotherapy. Single-agent treatment with rituximab or prednisone was not regarded as cytotoxic chemotherapy. Statistical significance between the Ki-67 PI and pathologic grade or progression of disease was calculated using a Wilcoxon 1-tailed rank sum test. Pathologic grade was compared with progression of disease using a Fisher exact test. Results Value Version 9.1 View width 1, View height 1, Overlap size 1 Image zoom 1 Classifier None Classifier neighborhood Averaging radius (pixels) 3 Curvature threshold 1 Segmentation type 1 Threshold type 2 Lower intensity threshold Upper intensity threshold 2 Minimum nuclear size (pixels) 8 Maximum nuclear size (pixels) 1,2 Minimum roundness.1 Minimum compactness Minimum elongation.1 Remove light objects Weak (1+) threshold 19 Moderate (2+) threshold 1 Strong (3+) threshold 1 Black threshold Edge trim Weighted Markup image type Analysis Nuclear red OD Nuclear green OD Nuclear blue OD Positive red OD Positive green OD Positive blue OD Color (3) red OD Color (3) green OD Color (3) blue OD Clear area intensity 24 Use mode Analysis/tuning Classifier type IHC nuclear Classifier definition file IHC nuclear training IHC, immunohistochemistry; OD, optical density. Thirty-one cases of FL were identified, including 19 cases that were WHO grade 1 to 2 and 12 cases that were WHO grade 3 Table 2. We first assessed the validity of the software-automated counts. To accomplish this, 3 cases of Table 2 Clinical and Pathologic Features of 31 Cases of FL Case No. Age, y Sex Location FL Grade 1 81 F Axillary LN M Shoulder mass F Mesenteric LN M Axillary LN M Shoulder mass M Cervical LN F Thigh mass M Inguinal LN M Chest wall mass M Cheek lesion M Upper chest skin F Cervical LN F Uterine mass F Axillary LN M Pancreatic mass F Scalp mass M Axillary LN F Elbow mass M Tracheal LN M L3 spine 3A M Axillary LN 3A F Inguinal LN 3A F Rectal LN 3A F Supraclavicular LN 3A 25 6 F Groin mass 3B 26 6 F Mesenteric LN 3B 27 5 M Axillary LN 3B F Axillary LN 3B F Axillary LN 3B 3 79 F Groin mass 3B F Thyroid mass 3B FL, follicular lymphoma; LN, lymph node. FL were selected that demonstrated low, medium, and high PI levels. For each case, images of all 1 selected fields were manually counted for both positive and negative nuclei Image 1. Ki-67 PI was also estimated in all fields by 5 experienced hematopathologists (M.V.-R., C.D.G., K.H.B., M.J.B., and A.S.D.) who did not have knowledge of the tumors histologic grade or measured PI. Quantitation of PI by image analysis showed a strong positive correlation with the manual Ki-67 PI count (Pearson r =.99, P <.1) Figure 1. The software consistently counted greater numbers of both positive and negative nuclei per field, with an average of 1.9% more positive nuclei and 4.8% more negative nuclei. The percentage of Ki-67 positive nuclei was almost identical to those from the manual counts. In comparison, the Ki-67 PI estimates from hematopathologists slightly overestimated the PI in cases with a higher PI but showed no significant difference from the automated results in cases with lower PIs. The hematopathologists estimated a mean ± SD PI.7% ± 1.3% greater than the algorithm for low PI fields, 3.% ± 6.6% greater for the medium PI fields, and 8.% ± 5.3% greater for the set of high PI fields. Next, the Ki-67 PI of all 31 FL cases was compared with the original histologic grade. In keeping with the 28 WHO Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV 581 Samols_ indd 581
4 Samols et al / Ki-67 in Follicular Lymphoma B C D E F A Image 1 Automated and manual measurement of the Ki-67 proliferation index (PI). Representative examples of extracted fields from scanned Ki-67 immunohistochemical slides: high PI (A-D; B-D depict framed area in A) and low PI (E-H; F-H depict framed area in E) fields. Manual counts identified 2, positive and 1,415 negative nuclei for a PI of 58.6% (B) and 173 positive and 3,624 negative nuclei for a PI of 4.6% (F) for the high and low PI fields, respectively Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV Samols_ indd 582
5 AJCP / Original Article G (P =.2, Wilcoxon rank sum test) Figure 2B. A cutoff PI value of 15% strongly correlated with a need to treat in 4 of 5 untreated patients and in 2 of 2 treated patients falling below this threshold (P =.5, Fisher exact test). In our data set, intermediate histologic grade (WHO 3A/B) was not significantly associated with disease progression (P =.31, Fisher exact test). Discussion Follicular lymphoma is one of the most common lymphomas, but accurate grading of this neoplasm is difficult and shows relatively poor interobserver agreement.7,8 Current grading schemata rely on morphologic identification and quantitation of centroblasts; however, variations in fixation and staining can make this seemingly straightforward task relatively difficult. We investigated whether recent advances in the automated quantitation of IHC stains provide a reliable means to quantify the Ki-67 PI to improve the prognostication of FL. Our results show that the PI in FL neoplastic follicles determined using image analysis correlates strongly with precise Ki-67 PI counts performed manually. Hematopathologists had a tendency to overestimate PIs with higher Ki-67 staining, although their PI estimates were fairly accurate in the lower range; however, it should be noted that these estimates were not made in the normal course of reviewing slides but rather during a specific exercise estimating the exact field quantified by the software. The software-quantified PI was H The nuclear quantitation algorithm identified 2,6 positive (yellow) and 1,396 negative (blue) nuclei for a PI of 65.1% for the high PI field (C) and 216 positive and 3,672 negative nuclei for a PI of 5.6% for the low PI field (G). The Ki-67 images are overlaid with the algorithm results (outlines; yellow = positive; blue = negative) and the manual counts (dots; red = positive; green = negative), showing the close correlation for these methods (D, H). Samols_ indd Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV classification, a distinction was not made between grade 1 and grade 2 FL. Higher histologic grade was significantly associated with a higher PI; grade 1 to 2 FL had a median Ki-67 PI of 21.9%, and grade 3 FL had a median Ki-67 PI of 39.9% (P =.2, Wilcoxon 1-tailed rank sum test) Figure 2A. Although we were able to show a significant difference between the PI of low-grade (WHO 1-2) and intermediate-grade (WHO 3A/B) FL, we were unable to set a discrete cutoff value of PI to separate the grades completely since we found several cases with either low histologic grade and high PI or higher histologic grade and low PI. A second review of these discrepant cases confirmed the original histologic grading. At our institution, patients with FL typically do not require immediate treatment with cytotoxic chemotherapy or radiotherapy unless there is evidence of aggressive disease such as a large tumor mass, B symptoms, or organ compression. Due to the long natural history of FL and the fact that many of the selected cases were relatively recent, the need to treat with radiation therapy or cytotoxic chemotherapy was used as an end point rather than overall survival, and the clinician s decision to treat the patient was used as a marker for disease progression. Clinical follow-up data were available for 26 of the 31 FL cases. One patient with multiple medical problems died of other causes soon after the diagnosis of FL and was not included in the analysis. Of the remaining 25 patients, 5 received no treatment, 4 received radiation therapy, and 16 received cytotoxic chemotherapy Table 3. Higher PI was significantly associated with the need to treat; the 5 untreated patients had a median Ki-67 PI of 1.%, whereas the 2 treated patients had a median Ki-67 PI of 31.4%
6 Samols et al / Ki-67 in Follicular Lymphoma A 3, 2,5 Manual Algorithm Positive Cell Count 2, 1,5 1, 5 Med 1 Med 2 Med 3 Med 4 Med 5 Med 6 Med 7 Med 8 Med 9 Med 1 High 1 High 2 High 3 High 4 High 5 High 6 High 7 High 8 High 9 High 1 Low 1 Low 2 Low 3 Low 4 Low 5 Low 6 Low 7 Low 8 Low 9 Low 1 B C Negative Cell Count 5, 4, 3, 2, 1, 7 6 Manual Algorithm Field Med 1 Med 2 Med 3 Med 4 Med 5 Med 6 Med 7 Med 8 Med 9 Med 1 High 1 High 2 High 3 High 4 High 5 High 6 High 7 High 8 High 9 High 1 Low 1 Low 2 Low 3 Low 4 Low 5 Low 6 Low 7 Low 8 Low 9 Low 1 Manual Algorithm Field 5 4 PI Med 1 Med 2 Med 3 Med 4 Med 5 Med 6 Med 7 Med 8 Med 9 Med 1 High 1 High 2 High 3 High 4 High 5 High 6 High 7 High 8 High 9 High 1 Low 1 Low 2 Low 3 Low 4 Low 5 Low 6 Low 7 Low 8 Low 9 Low 1 Field 584 Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV Samols_ indd 584
7 AJCP / Original Article D 7 6 Algorithm Count PI Manual Count PI Figure 1 Validation of the algorithm-derived Ki-67 proliferation index (PI). The software algorithm counted an average of 1.9% more positive nuclei (A) and 4.8% more negative nuclei (B) for each field. However, the PI for each field was very similar to the algorithm, calculating on average a higher PI of 3.5% (C). The algorithm and manual counts for each field are plotted against each other, revealing a strong positive Pearson product-moment correlation (Pearson r =.99, df = 28, P <.1) with a slope of 1.4 (D). A Ki-67 PI (%) B Ki-67 PI (%) WHO 1-2 Lymphoma Grade WHO 3A/3B No Treatment Outcome Treatment Figure 2 Software-automated measurement of the proliferation index (PI) is associated with histologic grade and disease progression. A, Using a Wilcoxon 1-tailed rank sum test, higher PI showed a significant positive correlation with higher histologic grade; grade 1 to 2 follicular lymphoma (FL) had a median Ki-67 PI of 21.9% and grade 3 FL of 39.9% (P =.2). B, Higher PI was also significantly associated with the need to treat; untreated (n = 5) patients had a median Ki-67% of 1.% and treated (n = 2) patients of 31.4% (P =.2). In our data set, higher histologic grade was not significantly associated with disease progression (P =.31, Fisher exact test). WHO, World Health Organization. Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV 585 Samols_ indd 585
8 Samols et al / Ki-67 in Follicular Lymphoma Table 3 Proliferation Index (PI), Pathologic Grade, and Treatment for Cases With Available Clinical Information Case No. PI, % FL Grade a Treatment No treatment Radiation No treatment B No treatment Chemotherapy No treatment Chemotherapy B Chemotherapy Radiation A Chemotherapy Chemotherapy Chemotherapy Chemotherapy A Chemotherapy A Chemotherapy Radiation Chemotherapy Radiation B Chemotherapy B Chemotherapy No treatment Chemotherapy A Chemotherapy A Chemotherapy B Chemotherapy a Grades 1, 2, and 1 to 2 represent low-grade follicular lymphoma (FL); grades 3A and 3B represent intermediate-grade lymphoma. also associated with both histologic grade (3) and the need to treat. Although a cutoff value of PI to separate the histologic grades could not be defined, a PI cutoff of 15% strongly correlated with the need to treat. A previous study demonstrated that Ki-67 can show a significantly higher PI with grade 2 or 3 compared with grade 1 FL but could not demonstrate a significant difference between grade 2 and grade 3 FL. 21 When analyzing data from older cases that used the 3-tiered system, our data show similar results. Within our data set, 6 cases were designated as grade 1, 9 as grade 2, and 4 as grade 1 to 2. Excluding the cases graded 1 to 2, we were able to show significant differences in PI between grade 1 (median PI, 12.6%) and grade 2 (median PI, 35.4%; P =.5). FL grade 1 was also significantly different from FL grade 3 (median PI, 4.3%; P =.2). However, FL grade 2 was not significantly different from grade 3 (P =.14). When we used the newer 2-tiered grading system for all cases, there was a significant difference of PI between low-grade (WHO 1-2) and intermediate-grade (WHO 3A/B) FL (Figure 2A). Another finding that emerged from these data was that a subset of low-grade FL cases had a high PI. Wang et al 25 previously reported a similar group of histologically lowgrade FLs that had a PI ranging from 3% to 8%. They demonstrated that although cases of low-grade FL with a high PI had an unexpectedly longer 5-year disease-free survival than those with low-grade FL with low PI, these patients had a significantly shorter overall survival. These authors suggested that these high PI/low-grade FLs had similar clinical behavior to grade 3 FL and should be considered separately from grade 1 to 2 FL. Although more cases with a discrepancy between histologic grade and PI would be needed to prove this definitively, our data are consistent with the conclusions of Wang et al. In the current study, higher PI was significantly associated with the need to treat regardless of the histologic grade, suggesting that cases of low-grade FL with a higher PI clinically behave like a higher-grade neoplasm. For our data set, 1 histologically low-grade cases with a PI greater than 15% required treatment. These high PI/low-grade FLs that act aggressively may account for the lack of correlation between higher histologic grade and the need to treat in our data set. Other approaches have been made to automate grading of FL that do not depend on Ki-67 derived PI values. One group has developed an algorithm-based approach to count follicular center centroblasts using scanned H&E images The method uses CD3 and CD2 IHC stains to automatically identify follicles and then hpfs on a corresponding H&E image to identify centroblasts and determine FL grade. However, this approach had a high level of false positives, resulting in an approximately 1% positive predictive value for centroblast detection, and it was also affected by variability in fixation and staining. Different IHC stains besides Ki-67 have also been assessed for the grading of FL. Zhang et al 21 reported that SKP2, another proliferation marker, was positively associated with higher FL grade and could distinguish between FL grades 2 and 3, whereas Ki-67 could not. Llanos et al 11 found that Bcl-2 IHC stains were negatively associated with higher FL grade, although they lacked prognostic predictive value. In terms of outcomes, Björck et al 3 demonstrated that higher expression of cyclin B1 in FL was positively associated with a better response to cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone chemotherapy. It is thus possible that, in the future, an automated software grading system could incorporate data from multiple IHC stains to establish tumor grade and also provide additional information that will help guide treatment decisions. This study shows that image analysis provides an accurate and reproducible means to quantify Ki-67 immunostaining in FL. Existing commercial algorithms can be tuned to achieve PIs that closely agree with those determined by human observers performing manual counts. Computerassisted quantitation of Ki-67 labeling in FL is analogous to computer-assisted quantitation of Ki-67, estrogen receptor, or progesterone receptor in breast cancer and could be integrated into the clinical workflow in a similar manner. While the patient population in this study is relatively small, these data also demonstrate that there is a statistically significant 586 Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV Samols_ indd 586
9 AJCP / Original Article positive correlation between software-automated Ki-67 PI and both histologic grade and disease progression in FL. Thus, application of this new technology could provide a means by which current difficulties in FL grading are circumvented and may provide improved prognostic information for patients and clinicians. Address reprint requests to Dr Duffield: Dept of Pathology, The Johns Hopkins Medical Institutions, Weinberg 2242 Pathology, 41 N Broadway, Baltimore, MD ; aduffie1@jhmi. edu. References 1. Solal-Celigny P. Follicular lymphoma international prognostic index. Curr Treat Options Oncol. 26;7: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; Wahlin BE, Yri OE, Kimby E, et al. Clinical significance of the WHO grades of follicular lymphoma in a populationbased cohort of 55 patients with long follow-up times. Br J Haematol. 212;156: Jaffe ES, Harris NL, Stein H, et al, eds. Who Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting Airlie House, Virginia, November J Clin Oncol. 1999;17: Harris NL, Jaffe ES, Stein H, et al. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: Dardick I, Caldwell DR. Follicular center cell lymphoma: morphologic data relating to observer reproducibility. Cancer. 1986;58: Metter GE, Nathwani BN, Burke JS, et al. Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists: a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies. J Clin Oncol. 1985;3: Broyde A, Boycov O, Strenov Y, et al. Role and prognostic significance of the Ki-67 index in non-hodgkin s lymphoma. Am J Hematol. 29; 84: Bryant RJ, Banks PM, O Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology. 26;48: Llanos M, Alvarez-Argüelles H, Alemán R, et al. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol. 21;18: Martinez AE, Lin L, Dunphy CH. Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. Arch Pathol Lab Med. 27;131: Hasselblom S, Ridell B, Sigurdardottir M, et al. Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma. 28;49: Hatanaka Y, Hashizume K, Kamihara Y, et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest in breast carcinoma by image analysis. Pathol Int. 21;51: Słodkowska J, Filas V, Buszkiewicz E, et al. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio). Folia Histochem Cytobiol. 21;48: Ellis CM, Dyson MJ, Stephenson TJ, et al. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 25;58: López C, Lejeune M, Salvadó MT, et al. Automated quantification of nuclear immunohistochemical markers with different complexity. Histochem Cell Biol. 28; 129: Gokhale S, Rosen D, Sneige N, et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 27;15: Sharangpani GM, Joshi AS, Porter K, et al. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J Microsc. 27;226: Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995;85: Zhang K, Prichard JW, Yoder S, et al. Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. Hum Pathol. 27;38: Chabot-Richards DS, Martin DR, Myers OB, et al. Quantitative image analysis in the assessment of diffuse large B-cell lymphoma. Mod Pathol. 211;24: Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 21;23: Russ JC. Characterizing Shape in the Image Processing Handbook. 6th ed. Boca Raton, FL: CRC Press; 211: Wang SA, Wang L, Hochberg EP, et al. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol. 25;29: Belkacem-Boussaid K, Samsi S, Lozanski G, et al. Automatic detection of follicular regions in H&E images using iterative shape index. Comput Med Imaging Graph. 211;35: Cooper L, Sertel O, Kong J, et al. Feature-based registration of histopathology images with different stains: an application for computerized follicular lymphoma prognosis. Comput Methods Programs Biomed. 29;96: Kong H, Gurcan M, Belkacem-Boussaid K. Partitioning histopathological images: an integrated framework for supervised color-texture segmentation and cell splitting. IEEE Trans Med Imaging. 211;3: Sertel O, Lozanski G, Shana ah A, et al. Computer-aided detection of centroblasts for follicular lymphoma grading using adaptive likelihood-based cell segmentation. IEEE Trans Biomed Eng. 21;57: Björck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood. 25;15: Am J Clin Pathol 213;14: DOI: 1.139/AJCPTMA1F6LWYTQV 587 Samols_ indd 587
Solomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationMorphometric Characterization of Small Cell Lymphocytic Lymphoma
ARS Medica Tomitana - 2014; 4(79): 179-183 10.1515/arsm-2015-0002 Chisoi Anca 1, Aşchie Mariana 2, Poinăreanu I. 2 Morphometric Characterization of Small Cell Lymphocytic Lymphoma 1 Spitalul Clinic Judetean
More informationImage analysis in IHC overview, considerations and applications
Image analysis in IHC overview, considerations and applications Rasmus Røge, MD, Institute of Pathology, Aalborg University Hospital NordiQC workshop September 2016 Aalborg, Denmark Outline Theory Image
More informationCOMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME
COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME Maria Lunardi MD Anatomic Pathology Fracastoro Hospital San Bonifacio, Verona -Italy HER2-neu
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationCME/SAM. Olga Pozdnyakova, MD, PhD, 1 Svetlana Kondtratiev, MD, 1,2 Betty Li, MS, 1 Karry Charest, 1 and David M. Dorfman, MD, PhD 1.
Hematopathology / New Mastocytosis Flow Cytometry Approach High-Sensitivity Flow Cytometric Analysis for the Evaluation of Systemic Mastocytosis Including the Identification of a New Flow Cytometric Criterion
More informationNuclear morphometric study of Non- Hodgkin's Lymphoma (NHL)
Original Research Article Nuclear morphometric study of Non- Hodgkin's Lymphoma (NHL) Sridhar Reddy Erugula 1, P. Sujatha 2, Ayesha Sameera 3, B. Suresh Reddy 4, Jesudass Govada 5, G. Sudhakar 6, Kandukuri
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationFinal Project Report Sean Fischer CS229 Introduction
Introduction The field of pathology is concerned with identifying and understanding the biological causes and effects of disease through the study of morphological, cellular, and molecular features in
More informationMeasuring cell density in prostate cancer imaging as an input for radiotherapy treatment planning
Measuring cell density in prostate cancer imaging as an input for radiotherapy treatment planning Poster No.: R-0262 Congress: 2014 CSM Type: Scientific Exhibit Authors: H. Reynolds, S. Williams, A. Zhang,
More informationVisual interpretation in pathology
13 Visual interpretation in pathology Tissue architecture (alteration) evaluation e.g., for grading prostate cancer Immunohistochemistry (IHC) staining scoring e.g., HER2 in breast cancer (companion diagnostic
More informationCase 3. Ann T. Moriarty,MD
Case 3 Ann T. Moriarty,MD Case 3 59 year old male with asymptomatic cervical lymphadenopathy. These images are from a fine needle biopsy of a left cervical lymph node. Image 1 Papanicolaou Stained smear,100x.
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationCME/SAM. Mixed Phenotype Acute Leukemia
AJCP / Original Article Mixed Phenotype Acute Leukemia A Study of 61 Cases Using World Health Organization and European Group for the Immunological Classification of Leukaemias Criteria Olga K. Weinberg,
More informationCD5 Positive Follicular Lymphomas- A Diagnostic Dilemma in a Resource Restricted Laboratory Setting
Original Article DOI: 10.21276/APALM.1364 CD5 Positive Follicular Lymphomas- A Diagnostic Dilemma in a Resource Restricted Laboratory Setting Sakthi Sankari S 1 *, Arjunan A 2, Bhuvaneswari M.G. 2, Sindhuja
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationChapter 4. F.H. Heyning 1, P.C.W. Hogendoorn 2, M.H.H. Kramer 3, C.T.Q. Holland 2, E. Dreef 2, P.M. Jansen 2
Primary Lymphoma of Bone: Extranodal Lymphoma with Favourable Survival Independent of Germinal Centre, Post Germinal Centre, or Indeterminate Phenotype F.H. Heyning 1, P.C.W. Hogendoorn 2, M.H.H. Kramer
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationLearn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1
Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1 Expression of B-cell surface antigens drives several non-hodgkin s lymphomas (NHLs)
More informationFollicular Lymphoma: the WHO
Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure
More informationSignificance of MYC/BCL2 Double Expression in Diffuse Large B-cell Lymphomas: A Single-center Observational Preliminary Study of 88 Cases
Original Article Significance of MYC/BCL Double Expression in Diffuse Large B-cell Lymphomas: A Single-center Observational Preliminary Study of 88 Cases Chutima Pinnark 1 ; Jerasit Surintrspanont ; Thiamjit
More informationMantle Cell Lymphoma
HEMATOPATHOLOGY Original Article Mantle Cell Lymphoma Morphologic Findings in Bone Marrow Involvement JAY WASMAN, MD, 1 NANCY S. ROSENTHAL, MD,' AND DIANE C. FARHI, MD 2 Although mantle cell lymphoma (MCL),
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationDoes the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
Histopathology 2012, 61, 1214 1218. DOI: 10.1111/j.1365-2559.2012.04351.x SHORT REPORT Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationAn ImageJ Based Semi-Automated Morphometric Assessment of Nuclei in Oncopathology
Original Article DOI: 10.17354/ijss/2015/475 An ImageJ Based Semi-Automated Morphometric Assessment of Nuclei in Oncopathology Vijayashree Raghavan 1, K Ramesh Rao 2 1 Professor and Head, Department of
More informationMimics of Lymphoma in Routine Biopsies. I have nothing to disclose regarding the information to be reported in this talk.
Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco I have nothing to disclose regarding the information to be reported in this
More informationGeisinger Clinic Annual Progress Report: 2011 Nonformula Grant
Geisinger Clinic Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview The Geisinger Clinic received $1,000,000 in nonformula funds for the
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationThe following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details.
Disclaimer: The following slides were presented at the TIGA Workshop, and are enclosed in the PP show format (*.pps) in order to include all presented details. These slides are proprietary and should not
More informationJ of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 3/ Issue 19/May 12, 2014 Page 5307
PROGNOSTIC SIGNIFICANCE OF PROLIFERATIVE ACTIVITY (KI67 EXPRESSION) IN OSTEOSARCOMA IN CHILDREN Moumita Paul 1, Arnab Karmakar 2, Uttara Chatterjee 3, Uttam Kumar Saha 4, Koushik Saha 5, Nanda Dulal Chatterjee
More informationMimics of Lymphoma in Routine Biopsies. Mixed follicular and paracortical hyperplasia. Types of Lymphoid Hyperplasia
Mimics of Lymphoma in Routine Biopsies Patrick Treseler, MD, PhD Professor of Pathology University of California San Francisco Types of Lymphoid Hyperplasia Follicular hyperplasia (B-cells) Paracortical
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationAggressive B-cell Lymphomas Updated WHO classification Elias Campo
Aggressive B-cell Lymphomas Updated WHO classification Elias Campo Hospital Clinic, University of Barcelona Diffuse Large B-cell Lymphoma A Heterogeneous Category Subtypes with differing: Histology and
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationImmune Cell Phenotyping in Solid Tumors using Quantitative Pathology
Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology James R. Mansfield Director of Quantitative Pathology Applications 2009 PerkinElmer What is Quantitative Pathology? Quantitative Pathology
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationNUCLEI SEGMENTATION OF MICROSCOPY IMAGES OF THYROID NODULES VIA ACTIVE CONTOURS AND K-MEANS CLUSTERING
1 st International Conference on Experiments/Process/System Modelling/Simulation/Optimization 1 st IC-EpsMsO Athens, 6-9 July, 2005 IC-EpsMsO NUCLEI SEGMENTATION OF MICROSCOPY IMAGES OF THYROID NODULES
More informationAutomated Nuclei Segmentation Approach based on Mathematical Morphology for Cancer Scoring in Breast Tissue Images
Automated Nuclei Segmentation Approach based on Mathematical Morphology for Cancer 915 Automated Nuclei Segmentation Approach based on Mathematical Morphology for Cancer Scoring in Breast Tissue Images
More informationA Clinicopathologic Evaluation of Follicular Lymphoma Grade 3A Versus Grade 3B Reveals No Survival Differences
Clinicopathologic Evaluation of Follicular Lymphoma Grade 3 Versus Grade 3 Reveals o Survival Differences Eric D. Hsi, MD; Imran Mirza, MD; Gerard Lozanski, MD; John Hill, MD; rad Pohlman, MD; Matthew
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationMBP AP 3 Core Curriculum
MBP AP 3 Core Curriculum The MBP AP3 core curriculum focuses on providing pathologists with the knowledge and skills needed to be a vital member of the patient care team. Further, the curriculum fulfills
More informationAbstract. Anb Med J Vol.11 No.1; 62-68
Non-Hodgkin's Lymphoma: a Preliminary Morphometric Study Aiad Abdullah Abdulrazak Department of Pathology, Tikrit College of Medicine, University of Tikrit, Iraq Abstract Background: Assessment of nuclear
More informationCase Report Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report
Int J Clin Exp Pathol 2014;7(10):7076-7081 www.ijcep.com /ISSN:1936-2625/IJCEP0001940 Case Report Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report Ikuo Matsuda 1, Yoshifumi
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationDuring past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationClinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma
160 Original Article Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma Hong-wei Zhang 1,#, Niu-liang Cheng 1*, Zhen-wen Chen 2, Jin-fen Wang 3, Su-hong Li 3, Wei Bai 3 1 Department of Biochemistry
More informationLarge Colorectal Adenomas An Approach to Pathologic Evaluation
Anatomic Pathology / LARGE COLORECTAL ADENOMAS AND PATHOLOGIC EVALUATION Large Colorectal Adenomas An Approach to Pathologic Evaluation Elizabeth D. Euscher, MD, 1 Theodore H. Niemann, MD, 1 Joel G. Lucas,
More informationGaining New Insights Through IF Multiplexed Staining and Analysis. Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory October 5, 2017
Gaining New Insights Through IF Multiplexed Staining and Analysis Tyna Hope, Ph.D. P.Eng Biomarker Imaging Research Laboratory Assessing more from Tissue Sections Gaps with More Common Methods Most common
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationDoes digital IHC need digital tissue controls?
VILNIUS UNIVERSITY Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information system Arvydas Laurinavicius
More informationA CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey
A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck
More informationConjunctival CD5+ MALT lymphoma and review of literatures
ISPUB.COM The Internet Journal of Pathology Volume 8 Number 2 Conjunctival CD5+ MALT lymphoma and review of literatures M Fard Citation M Fard. Conjunctival CD5+ MALT lymphoma and review of literatures.
More informationPhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA
PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More information3/22/2017. Disclosure of Relevant Financial Relationships. Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017.
Disclosure of Relevant Financial Relationships Ki-67 in Pancreatic Neuroendocrine Neoplasms According to WHO 2017. USCAP requires that all planners (Education Committee) in a position to influence or control
More informationReproducibility of Histologic Classification in Nonfibrotic Myeloproliferative Neoplasia
Hematopathology / Morphologic Features in MPN Reproducibility of Histologic Classification in Nonfibrotic Myeloproliferative Neoplasia Suzanne M. Koopmans, MD, 1 Freek J. Bot, MD, PhD, 1,2 King H. Lam,
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationCase Report Transformation of a Cutaneous Follicle Center Lymphoma to a Diffuse Large B-Cell Lymphoma An Unusual Presentation
Case Reports in Medicine Volume 21, Article ID 296523, 5 pages doi:1.1155/21/296523 Case Report Transformation of a Cutaneous Follicle Center Lymphoma to a Diffuse Large B-Cell Lymphoma An Unusual Presentation
More informationInterpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio
Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing
More informationMinimizing Errors in Diagnostic Pathology
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville Medical Director, Shands Jacksonville Breast Health Center
More informationClinicopathologic Profile and Outcome of Extranodal Diffuse Large B-Cell NHL: Egyptian National Cancer Institute Experience
HeSMO 6(3) 2015 8 12 DOI: 10.1515/fco-2015-0013 Forum of Clinical Oncology Clinicopathologic Profile and Outcome of Extranodal Diffuse Large B-Cell NHL: Egyptian National Cancer Institute Experience Ola
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationShearWave elastography in lymph nodes
ShearWave elastography in lymph nodes Poster No.: B-0158 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific Paper F. Houari, O. Lucidarme, J. Gabarre, F. Charlotte, C. Pellot- Barakat, M. Lefort,
More information3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:
Pulmonary Pathology Specialty Conference Saul Suster, M.D. Medical College of Wisconsin Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position
More information11/8/2018 DISCLOSURES. I have NO Conflicts of Interest to Disclose. UTILTY OF DETECTING PATTERNS
Bharat N. Nathwani, M.D. City of Hope Medical Center Professor, Director of Pathology Consultation Services, 1500 East Duarte Road, Duarte, California, 91010 DISCLOSURES -------------------------------------------------------
More informationLymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients
Hematopathology / LYMPHOMAS WITH IGM PARAPROTEIN Lymphoid Neoplasms Associated With IgM Paraprotein A Study of 382 Patients Pei Lin, MD, 1 Suyang Hao, MD, 1* Beverly C. Handy, MD, 2 Carlos E. Bueso-Ramos,
More informationABERRANT EXPRESSION OF CD19 AND CD43
ABERRANT EXPRESSION OF CD19 AND CD43 IN A PATIENT WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND A HISTORY OF MANTLE CELL LYMPHOMA Yen-Chuan Hsieh, 1 Chien-Liang Lin, 2 Chao-Jung Tsao, 2 Pin-Pen Hsieh,
More informationAN ALGORITHM FOR EARLY BREAST CANCER DETECTION IN MAMMOGRAMS
AN ALGORITHM FOR EARLY BREAST CANCER DETECTION IN MAMMOGRAMS Isaac N. Bankman', William A. Christens-Barryl, Irving N. Weinberg2, Dong W. Kim3, Ralph D. Semmell, and William R. Brody2 The Johns Hopkins
More informationDigital Pathology and CAP Guidelines
Digital Pathology and CAP Guidelines Frequently asked questions The VENTANA family of digital pathology products empowers you with the convenience of a comprehensive image and workflow solution. When used
More informationThe prognostic role of p-53 protein Immunohistochemical expression in multiple myeloma
Original Article The prognostic role of p-53 protein Immunohistochemical expression in multiple myeloma * Abdulkareem M. Jaafar** Adel R. ALsaadawi *** MBChB MBChB, MSc,PhD MBChB, FICMS J Fac Med Baghdad
More informationComposite mantle cell and follicular lymphoma. A case report
Human Pathology (2009) 40, 259 263 www.elsevier.com/locate/humpath Case study Composite mantle cell and follicular lymphoma. A case report Raquel B. Ilgenfritz MD a,, Agnès Le Tourneau MD a, Michel Arborio
More informationPROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT
PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT Author: Dr Sally Ann Hales On behalf of the Breast and pathology CNGs Written: March 2005 Reviewed by CNG: June 2009 &
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationProtocol for the Examination of Specimens From Patients With Hodgkin Lymphoma*
Protocol for the Examination of Specimens From Patients With Hodgkin Lymphoma* Version: Hodgkin 3.1.0.1 Protocol Posting Date: October 2013 This protocol is NOT required for accreditation purposes *This
More informationBioimaging and Functional Genomics
Bioimaging and Functional Genomics Elisa Ficarra, EPF Lausanne Giovanni De Micheli, EPF Lausanne Sungroh Yoon, Stanford University Luca Benini, University of Bologna Enrico Macii,, Politecnico di Torino
More informationBreast cancer diagnostic solutions Deliver diagnostic confidence
Breast cancer diagnostic solutions Deliver diagnostic confidence 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationSmad1 Expression in Follicular Lymphoma
Journal of Pathology and Translational Medicine 2015; 49: 243-248 ORIGINAL ARTICLE Smad1 Expression in Follicular Lymphoma Jai Hyang Go Department of Pathology, Dankook University College of Medicine,
More informationCase Report Precursor B Lymphoblastic Lymphoma Involving the Stomach
Volume 2013, Article ID 930918, 4 pages http://dx.doi.org/10.1155/2013/930918 Case Report Precursor B Lymphoblastic Lymphoma Involving the Stomach Masaya Iwamuro, 1,2 Yoshinari Kawai, 1 Yasuhide Yamawaki,
More informationNeuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
More informationHER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade
Anatomic Pathology / HER2/NEU AMPLIFICATION IN BREAST CANCER HER2/neu Amplification in Breast Cancer Stratification by Tumor Type and Grade Elise R. Hoff, MD, Raymond R. Tubbs, DO, Jonathan L. Myles, MD,
More informationComputer Assisted Detection and Analysis of Tall Cell Variant Papillary Thyroid Carcinoma in Histological Images
Computer Assisted Detection and Analysis of Tall Cell Variant Papillary Thyroid Carcinoma in Histological Images Edward Kim 1, Zubair Baloch 2, Caroline Kim 3 1 Department of Computing Sciences, Villanova
More informationHER2 FISH pharmdx TM Interpretation Guide - Breast Cancer
P A T H O L O G Y HER2 FISH pharmdx TM Interpretation Guide - Breast Cancer For In Vitro Diagnostic Use FDA approved as an aid in the assessment of patients for whom Herceptin TM (trastuzumab) treatment
More informationNext generation image analysis for immunohistochemistry quantitation
Next generation image analysis for immunohistochemistry quantitation Ben Vainer Department of Pathology, Rigshospitalet University of Copenhagen Medical Center Men are only so good as their technical developments
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More information